Ipsen and bioMérieux have created a global collaboration in theranostics with a focus on hormone-dependent cancers. The partnership emphasizes the companies' expertise in the emerging field of personalized medicine. The companies will identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors and pituitary tumors. BioMérieux got into the arena of molecular diagnostics in 2008 through the $60 million purchase of San Diego company AviaraDx. AviaraDx had developed methods of testing the molecular biology of a sample in order to diagnose cancer. Ipsen/bioMérieux release | News